{"id":17912,"date":"2023-12-26T19:41:34","date_gmt":"2023-12-26T19:41:34","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/?p=17912"},"modified":"2023-12-26T19:41:34","modified_gmt":"2023-12-26T19:41:34","slug":"life-science-raw-ingredients-will-2024-be-the-year-of-recovery","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/","title":{"rendered":"Life science raw ingredients: will 2024 be the year of recovery?"},"content":{"rendered":"<p>Global trade in key raw materials for animal and human health <strong>is starting to return to pre-crisis levels.<\/strong> After four consecutive quarters of weak trade volumes,<strong> the data for the third quarter of 2023 leaves us well hope<\/strong>indicating a recovery from the trend line historical.<\/p>\n<p>However, experts warn that <strong>the next two quarters will be crucial<\/strong> to confirm the solidity of this recovery.<\/p>\n<p>This is stated in the report <a href=\"https:\/\/kemiex.com\/news\/current-state-of-raw-materials\" target=\"_blank\" rel=\"noopener\">&#8220;Current state of raw materials\u201d<\/a>, a report on \u201c<strong>how the life sciences raw materials industry sees itself in difficult times<\/strong>\u201d published by Kemiex, a digital trading platform specializing in active pharmaceutical ingredients, additives, vitamins, amino acids , minerals, phosphates and other food and feed additives.<\/p>\n<p>The company conducted <strong>a survey among its customers and professionals in the raw materials sector<\/strong> to measure their &#8220;sentiment&#8221; at the end of (another) challenging year for manufacturing and trade.<\/p>\n<blockquote class=\"td_pull_quote td_pull_center\"><p>Data collected by industry professionals provides valuable insights into the outlook for industry industries in 2024.<\/p><\/blockquote>\n<p style=\"text-align: center;\"><strong>Stefan Schmidinger,<\/strong><br \/>\n<strong>Head of Market &amp; Supply Chain Research, Kemiex<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>In 2022, a concatenation of events that began in 2021 \u2013 such as struggling transport markets and the blockade of the Suez Canal, China&#8217;s energy shortage, emissions controls ahead of the Beijing Olympics, soaring prices, the ongoing crisis Ukraine \u2013 have generated a sudden contraction in demand in several sectors causing excess inventories for many companies.<\/p>\n<h2>Hopes for 2024<\/h2>\n<p>2023 has shown signs of recovery but the main expectations are focused on the beginning of the new year: according to the survey results, <strong>only 14% of those interviewed have already experienced a growth<\/strong> in commercial activity in the first three quarters of 2023 with an additional 15% counting on the results of the last quarter.<\/p>\n<p><strong>The majority of professionals (35%<\/strong>), however, have greater optimism for economic growth <strong>in the first half of 2024<\/strong>, while another <strong>19%<\/strong> &gt; is inclined to expect an increase in the <strong>second half of the year<\/strong>. The authors of the Pongo report also highlight that 17% expect a slower expansion, postponing growth expectations beyond 2025.<\/p>\n<p><span style=\"color: #3366ff;\">The judgment on the current market dynamics<\/span> is consistent with these data: analyzing the purchase and sale volumes and the number of requests and transactions compared to the last 24 months, the majority of survey participants expressed a moderate opinion: 35% described the business as moderately traded, reporting stable but not significant growth. <strong>31% rated the activity as regular<\/strong>, suggesting a healthy market situation but with some limitations.<\/p>\n<p><strong>Only 10% observed very active trade <\/strong>(level 5), while 12% defined it as active, a sign of strong growth but some (slight) limitations. <strong>4% rated the lowest level,<\/strong> judging their commercial activity to be slow.<\/p>\n<h2>A difficult commercial context<\/h2>\n<p>According to the protagonists, the performance of companies is mainly affected by <span style=\"color: #3366ff;\">three factors, all of a commercial nature<\/span>: <strong>fierce price competition (54%), the decline in customer orders and shorter planning cycles (52%), an excess of inventory resulting in its reduction (50%)<\/strong>.<br \/>\nThe socioeconomic context, however, also plays a significant role in influencing company results. In fact, critical factors emerge, <em>primarily<\/em> the <strong>increase in prices<\/strong> <strong>of raw materials and energy,<\/strong> reported by 40% of respondents as one of the main challenges.<\/p>\n<p>Furthermore, 37% highlighted inflation and the resulting <strong>drop in purchasing power<\/strong> as additional stressors for companies and 25% highlighted <strong>the increase in interest rates <\/strong>which impacts financing, working capital and inventory management, thus further testing the resilience of businesses in an already complex economic context.<\/p>\n<h2>&#8230;but the mood remains positive<\/h2>\n<p>Despite the difficulties, the interviewees&#8217; perception of the company&#8217;s performance was positive: when the participants to choose an emoji that best represented their company or business unit&#8217;s profit performance in 2023, <strong>35% opted for an emoji that symbolizes a positive outlook, 25% chose an emoji that represents an average performance, and 15% selected an emoji that expresses a very positive trend.<\/strong> On the opposite side, 15% indicated a slightly negative performance while 10% chose an emoji that represents a significant decrease in profits.<\/p>\n<p><script src=\"https:\/\/cdn.jsdelivr.net\/npm\/chart.js\"><\/script><br \/>\n<canvas id=\"profitChart\" style=\"margin-top: -10px;\" width=\"400\" height=\"200\"><\/canvas><br \/>\n<script>\n        var ctx = document.getElementById('profitChart').getContext('2d');\n        var profitChart = new Chart(ctx, {\n            type: 'bar',\n            data: {\n                labels: ['Excitement', 'Satisfaction', 'Indifferent', 'Unhappy', 'Dissapointment'],\n                datasets: [{\n                    label: 'Response rate',\n                    data: [15, 35, 25, 15, 10],\n                    backgroundColor: [\n                        'rgba(54, 162, 235, 0.6)',\n                        'rgba(75, 192, 192, 0.6)',\n                        'rgba(153, 102, 255, 0.6)',\n                        'rgba(255, 206, 86, 0.6)',\n                        'rgba(255, 99, 132, 0.6)'\n                    ],\n                    borderColor: [\n                        'rgba(54, 162, 235, 1)',\n                        'rgba(75, 192, 192, 1)',\n                        'rgba(153, 102, 255, 1)',\n                        'rgba(255, 206, 86, 1)',\n                        'rgba(255, 99, 132, 1)'\n                    ],\n                    borderWidth: 1\n                }]\n            },\n            options: {\n                scales: {\n                    y: {\n                        beginAtZero: true,\n                        ticks: {\n                            callback: function(value, index, values) {\n                                return value + '%';\n                            }\n                        }\n                    }\n                },\n                plugins: {\n                    legend: {\n                        display: false\n                    }\n                }\n            }\n        });\n    <\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.<\/p>\n","protected":false},"author":4,"featured_media":17917,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[812,796],"tags":[854,1014],"class_list":{"0":"post-17912","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-api-excipients","8":"category-market","9":"tag-api-en","10":"tag-raw-materials"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Life science raw ingredients: will 2024 be the year of recovery? - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Life science raw ingredients: will 2024 be the year of recovery? - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-26T19:41:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"457\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Simone Montonati\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Simone Montonati\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\"},\"author\":{\"name\":\"Simone Montonati\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/f3aa43695ff057a62d2d6b95c536be17\"},\"headline\":\"Life science raw ingredients: will 2024 be the year of recovery?\",\"datePublished\":\"2023-12-26T19:41:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\"},\"wordCount\":638,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg\",\"keywords\":[\"API\",\"raw materials\"],\"articleSection\":[\"API &amp; Excipients\",\"Market\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\",\"name\":\"Life science raw ingredients: will 2024 be the year of recovery? - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg\",\"datePublished\":\"2023-12-26T19:41:34+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/f3aa43695ff057a62d2d6b95c536be17\"},\"description\":\"According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg\",\"width\":800,\"height\":457},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Life science raw ingredients: will 2024 be the year of recovery?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/f3aa43695ff057a62d2d6b95c536be17\",\"name\":\"Simone Montonati\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g\",\"caption\":\"Simone Montonati\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/simone-montonati\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Life science raw ingredients: will 2024 be the year of recovery? - MakingPharmaIndustry","description":"According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/","og_locale":"en_US","og_type":"article","og_title":"Life science raw ingredients: will 2024 be the year of recovery? - MakingPharmaIndustry","og_description":"According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2023-12-26T19:41:34+00:00","og_image":[{"width":800,"height":457,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg","type":"image\/jpeg"}],"author":"Simone Montonati","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Simone Montonati","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/"},"author":{"name":"Simone Montonati","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/f3aa43695ff057a62d2d6b95c536be17"},"headline":"Life science raw ingredients: will 2024 be the year of recovery?","datePublished":"2023-12-26T19:41:34+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/"},"wordCount":638,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg","keywords":["API","raw materials"],"articleSection":["API &amp; Excipients","Market"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/","name":"Life science raw ingredients: will 2024 be the year of recovery? - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg","datePublished":"2023-12-26T19:41:34+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/f3aa43695ff057a62d2d6b95c536be17"},"description":"According to a survey of raw material traders in the food and pharmaceutical industries, the highest expectations for growth are concentrated in the first six months of the new year.","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/12\/Raw-materials.jpg","width":800,"height":457},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/life-science-raw-ingredients-will-2024-be-the-year-of-recovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Life science raw ingredients: will 2024 be the year of recovery?"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/f3aa43695ff057a62d2d6b95c536be17","name":"Simone Montonati","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g","caption":"Simone Montonati"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/simone-montonati\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/17912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=17912"}],"version-history":[{"count":5,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/17912\/revisions"}],"predecessor-version":[{"id":17920,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/17912\/revisions\/17920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/17917"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=17912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=17912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=17912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}